On Thursday, Shares of Walt Disney Co (NYSE:DIS), gained 2.08% to $107.93.
Disney Consumer Products and Interactive Media (DCPI) and Hasbro, launched Playmation Marvel’s Avengers – the next step in the evolution of play. The groundbreaking system of connected toys and wearables fuses technology and digital storytelling to create a completely new category of play. Hitting shelves across the U.S. and Canada for the first time recently, the new toy/game hybrid aims to inspire both kids and parents to get active and creative at playtime.
Dreamed up by a team of technologists, Imagineers and storytellers from across The Walt Disney Company, Playmation is the culmination of extensive research into the world of play, highlighting the opportunity for a new type of experience that combines digital technology and physical, real-world play.
The online study of 2,000 families across the country confirms that almost all parents believe active playtime is essential to their child’s healthy development, and three say that using technology is a favorite way for their child to play. Four out of five parents say their children are more likely to engage with a game if technology is involved, and nine out of ten are open to new technologies that encourage their kids to be more active.
The Walt Disney Company, together with its auxiliaries, operates as an entertainment company worldwide. The company operates in five segments: Media Networks, Parks and Resorts, Studio Entertainment, Consumer Products, and Interactive.
Shares of Five Prime Therapeutics Inc (NASDAQ:FPRX), inclined 65.17% to $27.93, during its last trading session.
Five Prime Therapeutics, , will host a conference call and live audio webcast recently, October 15 at 8:30 a.m. (ET)/5:30 a.m. (PT) to discuss the new worldwide license and partnership agreement signed with Bristol-Myers Squibb for FPA008, Five Prime’s CSF1R antibody program.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates comprise FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ib clinical trials for the treatment of rheumatoid arthritis; and in pre-IND stage for pigmented villonodular synovitis and multiple cancers in combination with nivolumab.
Finally, Altria Group Inc (NYSE:MO), ended its last trade with 0.54% gain, and closed at $57.86.
Altria Group, will host a live audio webcast on Thursday, October 29, 2015, at 9:00 a.m. Eastern Time to discuss its 2015 third-quarter business results. Altria will issue a press release containing its business results at about 7:00 a.m. Eastern Time the same day. The webcast can be accessed at altria.com or through the Altria Investor App.
During the webcast, Marty Barrington, Altria’s Chairman, CEO and President, and Billy Gifford, Chief Financial Officer, will discuss the Company’s 2015 third-quarter business results and answer questions from the investment community and news media.
Altria Group, Inc., through its auxiliaries, manufactures and sells cigarettes, smokeless products, and wine in the United States and internationally. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, Husky, and Marlboro Snus brand names.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
